News
Allon Therapeutics releases first quarter 2013 operating results
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced its unaudited operating results for the three months ended March 31, 2013. During the fourth quarter of 2012, Allon announced that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for... Continue reading
Posted in News Releases
Allon reports 2012 audited operating results
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced its audited operating results for 2012. During the fourth quarter of 2012, Allon announced that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PS... Continue reading
Posted in News Releases
Allon provides shareholder update
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that its previously announced strategic review has generated a number of different strategic alternatives and opportunities that are being actively evaluated. The Company is aggressively managing ongoing operating expenses. Th... Continue reading
Posted in News Releases
Allon director takes new role
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that Mr. Michael Aldridge, Director of the Company since June 2011, has resigned to accept a new professional responsibility in the biotech industry. “We are grateful for Michael’s involvement and expertise, which contributed t... Continue reading
Posted in News Releases
Allon cuts staff and administrative costs
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that, after the negative results in its pivotal davunetide study, it has implemented staff and administrative reductions. As part of this process approximately 40% of its staff has been terminated. These changes are consistent ... Continue reading
Posted in News Releases